Piper Sandler Initiates Coverage On Day One Biopharmaceutical with Overweight Rating, Announces Price Target of $44
Piper Sandler analyst Erinn Murphy initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight rating and announces Price Target of $44.